Latest Ratios: P/E Ratio -11.6x · EV/EBITDA N/A · ROE -62.5%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $477M | $289M | $387M | $191M | $760M | — | — |
| Enterprise Value | $1.6B | $463M | $258M | $330M | $154M | $527M | — | — |
| P/E Ratio → | -11.60 | — | — | — | — | — | — | — |
| P/S Ratio | 589.57 | 170.48 | 63.70 | 67.60 | 33.20 | 158.87 | — | — |
| P/B Ratio | 7.04 | 2.52 | 1.61 | 2.19 | 0.70 | 2.08 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 165.22 | 56.84 | 57.72 | 26.76 | 110.24 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -319.4% | -319.4% | -1277.6% | -731.9% | -925.0% | -832.4% | -139.5% | 100.0% |
| Operating Margin | -4454.2% | -4454.2% | -2401.6% | -2020.2% | -1857.5% | -1573.4% | -278.3% | -304.1% |
| Net Profit Margin | -4113.7% | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | -300.3% | -319.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -62.5% | -62.5% | -58.0% | -49.1% | -32.8% | -46.6% | -111.1% | — |
| ROA | -53.6% | -53.6% | -47.9% | -41.1% | -28.1% | -39.2% | -26.6% | -33.8% |
| ROIC | -58.0% | -58.0% | -61.0% | -48.5% | -43.2% | -77.7% | — | — |
| ROCE | -65.9% | -65.9% | -58.4% | -48.3% | -31.3% | -32.0% | -28.2% | -39.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.06 | 0.09 | 0.08 | 0.05 | 0.22 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.17 | -0.32 | -0.13 | -0.64 | -0.83 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -549.78 | -549.78 | -190.24 | -92.75 | -107.40 | -21.66 | -21.64 | -23.57 |
Net cash position: cash ($20M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.57 | 6.57 | 4.67 | 4.08 | 6.17 | 8.07 | 7.25 | 3.94 |
| Quick Ratio | 6.57 | 6.57 | 4.67 | 4.08 | 5.68 | 7.75 | 7.25 | 3.94 |
| Cash Ratio | 6.34 | 6.34 | 3.92 | 3.30 | 5.43 | 7.46 | 6.92 | 3.78 |
| Asset Turnover | — | 0.01 | 0.02 | 0.03 | 0.02 | 0.01 | 0.05 | 0.11 |
| Inventory Turnover | — | — | — | — | 3.92 | 4.24 | — | — |
| Days Sales Outstanding | — | — | — | 139.73 | 98.44 | 108.77 | 121.72 | 39.34 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $137M | $110M | $92M | $91M | $93M | $92M | $92M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABSI stock.
Absci Corporation's current P/E ratio is -11.6x. This places it at the 50th percentile of its historical range.
Absci Corporation's return on equity (ROE) is -62.5%. The historical average is -60.0%.
Based on historical data, Absci Corporation is trading at a P/E of -11.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Absci Corporation has -319.4% gross margin and -4454.2% operating margin.
Key Metrics
Top Statement Risk
Cash runway insufficient
Metrics are mathematically derived from official filings.
Negative Margins Reflect Pre-Scale Model
Absci's gross margin deteriorated to -319.4% TTM, with operating margin at -4454%, indicating direct costs far exceed revenue, as reported in financial statements.
The gross margin swing from 100% in 2025Q3 to -33.5% in 2025Q2 and -11.7% in 2026Q1 suggests revenue recognition is highly volatile and tied to specific contract phases, not a stable cost structure. Operating losses have remained in the $23-$36 million range per quarter despite revenue fluctuations, implying fixed R&D and SG&A costs dominate. This indicates the company is subsidizing early-stage proof-of-concept work, and margins will only inflect if the platform transitions to high-margin royalty streams or scaled automation.
Persistent Negative Returns on Capital
ROIC has hovered between -10% and -15% over the past ten quarters, with ROE around -15%, indicating consistent value destruction, per quarterly data.
Despite a strengthened balance sheet with equity rising to $246.1 million in 2026Q2, returns on capital remain deeply negative, reflecting that the invested capital is not generating any positive return. The slight improvement in ROIC from -15.5% in 2025Q2 to -13.5% in 2026Q1 is likely due to a larger capital base rather than operational improvement. This suggests the company is in a pre-revenue phase where returns will remain negative until the platform achieves commercial scale, and investors should monitor whether any partner milestones can shift this trajectory.
Working Capital Efficiency Masked by Burn
Asset turnover is near zero at 0.00, while DSO spiked to 207 days in 2025Q3, indicating minimal revenue generation relative to assets, per financial data.
The near-zero asset turnover reflects the company's minimal revenue base relative to its substantial asset base, which is dominated by cash and R&D infrastructure. DSO volatility, from 3 days in 2024Q2 to 207 days in 2025Q3, suggests that revenue recognition is lumpy and tied to milestone achievements, not consistent invoicing. The negative cash conversion cycle, driven by high DPO, indicates the company is delaying supplier payments, but this is not a sign of operational efficiency; rather, it reflects the company's limited bargaining power and cash conservation efforts.
Minimal Debt Masks Refinancing Risk
Debt-to-equity fell to 0.02 in 2026Q2 from 0.06 a year earlier, with interest coverage deeply negative, indicating low leverage but high cash burn, per balance sheet data.
The low debt levels suggest the company is not reliant on debt financing, but the negative interest coverage (e.g., -1644 in 2026Q1) indicates that operating losses far exceed any interest expense, making debt service irrelevant at current scale. The de-risked capital structure provides flexibility, but the company's reliance on equity financing is evident from the capital infusion that boosted equity in 2026Q2. Investors should monitor whether the company can secure additional funding without diluting shareholders, as the current cash runway appears limited.
Liquidity Buffer Temporarily Strengthened
Current ratio improved to 10.63 in 2026Q2 from 6.59 in 2026Q1, with cash at $107.9 million, but quarterly burn exceeds $30 million, per balance sheet data.
The current ratio is exceptionally high, indicating ample short-term assets to cover liabilities, but this is largely due to cash raised from capital infusions, not operational profitability. With quarterly operating losses exceeding $30 million, the $107.9 million cash balance implies a runway of roughly three quarters, which is shorter than the headline liquidity suggests. The quick ratio equals the current ratio, indicating no inventory dependence, but the company's ability to withstand stress depends on its ability to raise additional capital or reduce burn.
Misapplied P/S Ratio Obscures Platform Value
The P/S ratio of 569.3 is misleading for a pre-revenue biotech, as it ignores the potential value of proprietary data and platform optionality, per valuation data.
Traditional valuation multiples like P/S and EV/EBITDA are not meaningful for Absci because revenue is minimal and not representative of the company's intrinsic value. The market appears to be pricing the company based on the optionality of its generative AI platform and the potential for future milestone payments, not current sales. Instead, investors should focus on metrics like burn-per-program, active program count, and the in-silico to in-vitro hit rate, which better capture the platform's progress and potential for step-function revenue changes.